Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563507 · ClinicalTrials.gov registry record · Phase 2
Combined Immunotherapies in Metastatic ER+ Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 3
- Study locations
NCT04563507: Recruiting Phase 2 study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
NCT04563507 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 102 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04563507, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 3
- Study locations
Study Summary
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Primary Outcome
Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death.
Conditions Studied
Interventions
- DRUG Palbociclib 125mg
- RADIATION Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
- DRUG Letrozole 2.5Mg Tab
Study Locations (3)
New York
- Weill Cornell Medicine - New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 2 |
What NCT04563507 shows while recruiting
NCT04563507 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Palbociclib 125mg is the first listed.
NCT04563507 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04563507 about?
NCT04563507 is a clinical study titled "Combined Immunotherapies in Metastatic ER+ Breast Cancer". Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic...
What is the current status of trial NCT04563507?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2020-11-12. Estimated completion is 2028-10-31.
What conditions does trial NCT04563507 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04563507?
The interventions under investigation include: Palbociclib 125mg (DRUG), Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) (RADIATION), Letrozole 2.5Mg Tab (DRUG).
Who is sponsoring clinical trial NCT04563507?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04563507 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04563507's enrollment target sits among peer trials
102 557th of 1224 higher than 664 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- NCT04873050 · 102 participants · Phase 4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI